A.V. NALYOTOV¹, JA.A. SOCKAJA², P.I. NALYOTOVA³

¹М. Gorky Donetsk State Medical University, Donetsk

²Lugansk State Medical University named after St. Luke, Donetsk

³Donetsk Central City Clinical Hospital No. 1, Donetsk

 Contact details:

Nalyotov A.V. — MD, Professor, Head of the Department of Pediatrics No. 2

Address: 16 prospekt Ilyicha, 283003 Donetsk, Donetsk People’s Republic, Russian Federation, tel.: +7960-467-52-98, e-mail: nalyotov-a@mail.ru

 The purpose — by using a noninvasive hydrogen breath test, to determine the frequency of small intestine bacterial overgrowth syndrome (BOS) in patients with IBS who have had COVID-19.

Material and methods. The study involved 148 patients suffering from IBS with a predominance of diarrhea. Group I included 88 patients who developed irritable bowel syndrome due to the new coronavirus infection. Group II consisted of 60 patients whose disorder was caused by stress. The control group included 30 relatively healthy subjects. The exhaled hydrogen analyzer LactofaN2 (AMA LLC, Russia) was used to diagnose the small intestine BOS in all patients.

Results. Among patients with irritable bowel syndrome with a predominance of diarrhea who suffered from COVID-19, the majority were diagnosed with bacterial overgrowth syndrome — 76 (86.3%) patients, which was statistically significantly (p < 0.01) more frequent compared to group II — patients with stress-induced disorder (32 patients (53.3%)).

Conclusions. Small intestine bacterial overgrowth syndrome is reported with high frequency in patients with irritable bowel syndrome who have suffered COVID-19. Microbial imbalance in the small intestine among patients in this group is significantly more common than in patients with classical stress-induced irritable bowel syndrome.

Key words: irritable bowel syndrome, small intestine bacterial overgrowth, COVID-19, post-COVID syndrome.

REFERENCES

1. Grinevich V.B., Lazebnik L.B., Kravchuk Yu.A. et al. Digestive system disorders in post-COVID syndrome. Clinical guidelines. Eksperimental’naya i klinicheskaya gastroenterologiya, 2022, vol. 208, no. 12, pp. 4–68 (in Russ.). DOI: 10.31146/1682-8658-ecg-208-12-4-68
2. Boraeva T.T., Ataeva M.V., Khirikhanova A.A. et al. Frequency of cardiovascular pathology and consequences of SARS-COV-2 virus infection in children of the Republic of North Ossetia-Alania. Meditsina. Sotsiologiya. Filosofiya. Prikladnye issledovaniya, 2023, no. 6, pp. 151–154 (in Russ.).
3. Marasco G., Maida M., Cremon G. et al. Meta-analysis: Post-COVID-19 functional dyspepsia and irritable bowel syndrome. Aliment. Pharmacol. Ther, 2023, vol. 58 (1), pp. 6–15. DOI: 10.1111/apt.17513
4. Huang L., Li X., Gu X. et al. Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. Lancet Respir. Med, 2022, vol. 10 (9), pp. 863–876. DOI: 10.1016/S2213–2600(22)00126–6
5. Settanni C.R., Ianiro G., Ponziani F.R. et al. COVID-19 as a trigger of irritable bowel syndrome: A review of potential mechanisms. World J. Gastroenterol, 2021, vol. 27, pp. 7433–7445. DOI: 10.3748/wjg.v27.i43.7433
6. Carfì A., Bernabei R., Landi F. Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients after Acute COVID-19. JAMA, 2020, vol. 324, P. 603–605. DOI: 10.1001/jama.2020.12603
7. Taribagil P., Creer D., Tahir H. “Long COVID” syndrome. BMJ Case Rep, 2021, vol. 14, pp. 241485. DOI: 10.1136/bcr-2020-241485
8. Naletov A.V., Masyuta D.I., Chalaya L.F. Pathogenetic basis of irritable bowel syndrome in patients who have had COVID-19. Mat’ i Ditya v Kuzbasse, 2021, vol. 4, no. 87, pp. 12-16 (in Russ.).
9. Batiha G.E., Al-Kuraishy H.M., Al-Gareeb A.I. et al. Pathophysiology of Post-COVID syndromes: A new perspective. Virol. J, 2022, vol. 19, p. 158. DOI: 10.1186/s12985-022-01891-2
10. Gu S., Chen Y., Wu Z. et al. Alterations of the gut microbiota in patients with coronavirus disease 2019 or H1N1 influenza. Clin. Infect. Dis, 2020, vol. 71, pp. 2669–2678. DOI: 10.1093/cid/ciaa709
11. Liu Q., Mak J. W. Y., Su Q. et al. Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome. Gut, 2022, vol. 71, pp. 544–552. DOI: 10.1136/gutjnl-2021-325989
12. Zuo T., Zhang F., Lui G.C.Y. et al. Alterations in gut microbiota of patients with COVID-19 during time of hospitalization. Gastroenterology, 2020, vol. 159 (3), pp. 944–955. e8. DOI: 10.1053/j.gastro.2020.05.048
13. Khavkin A.I., Naletov A.V., Shumilov P.V., Sitkin S.I. Efficiency of dietary fiber in inflammatory bowel diseases. Voprosy detskoy dietologii, 2024, vol. 22 (2), pp. 74–81 (in Russ.). DOI: 10.20953/1727-5784-2024-2-74-81
14. Marasco G., Maida M., Cremon G. et al. Meta-analysis: Post-COVID-19 functional dyspepsia and irritable bowel syndrome. Aliment Pharmacol. Ther, 2023, vol. 58 (1), pp. 6–15. DOI: 10.1111/apt.17513
15. Penninger J.M., Grant M.B., Sung, J.J.Y. The role of angiotensin converting enzyme 2 in modulating gut microbiota, intestinal inflammation, and coronavirus infection. Gastroenterology, 2021, vol. 160, pp. 39–46. DOI: 10.1053/j.gastro.2020.07.067
16. Naletov A.V., Masyuta D.I., Guz N.P. Features of clinical manifestations of irritable bowel syndrome in children who have had COVID-19. Children’s medicine of the North-West, 2021, vol. 9 (2), pp. 45–49.
17. Ivashkin V.T., Maev I.V., Abdulganieva D.I. et al. Practical recommendations of the Scientific Community for the Promotion of Clinical Study of the Human Microbiome (SCSCHM) and the Russian Gastroenterological Association (RGA) for the diagnosis and treatment of bacterial overgrowth syndrome in adults. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii, 2022, vol. 32, no. 3, pp. 68–85 (in Russ.).
18. Ivashkin V.T., Maev I.V., Shelygin Yu.A. et al. Diagnosis and treatment of irritable bowel syndrome (Clinical guidelines of the Russian Gastroenterological Association and the Association of Proctologists of Russia). Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii, 2021, vol. 31, no. 5, pp. 74–95 (in Russ.). DOI: 10.22416/1382-4376-2021-31-5-74-95